MedTrace Logo

Evaluation of the Metabolome in Diverticular Disease

NCT01831323 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2014-10-17

No results posted yet for this study

Summary

To evaluate the effect of the probiotic formulation VSL#3 on the metabolome and microbiota of diverticular disease, comparing it with the effects exerted by supplementation with fibers, by rifaximin and by mesalazine, and assessing the evolution over time after each specific treatment

Conditions

  • Simple Diverticular Disease

Interventions

DIETARY_SUPPLEMENT

VSL#3

VSL#3

DRUG

Rifaximin

Rifaximin

DRUG

Mesalazine

Mesalazine

DIETARY_SUPPLEMENT

Psyllium

psyllium

Sponsors & Collaborators

  • S.Eugenio Hospital

    lead OTHER

Principal Investigators

  • Gianmarco Giorgetti · Sant'Eugenio Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-12-31
Completion
2015-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01831323 on ClinicalTrials.gov